Michael Z. Lin, MD, PhD : Taking the Pedal Off the Metal

Years Funded: 2011-2013

Designing Protein Switches to Control Oncolytic RNA Virus Replication
In the Lin Laboratory at the Stanford University Department of Neurobiology (Stanford, CA), Michael Z. Lin, MD, PhD, engineered a way to interrupt the reproduction of cancer cells without impairing the health of normal cells.

Read More
Khalid Shah, MS, PhD: Treating Brain Tumors – How can we approach this differently?

Years Funded: 2008-2011

Targeting Cell Survival and Apoptotic Pathways in Brain Tumors
By engineering adult stem cells, Khalid Shah, MS, PhD, and his team at the Center for Stem Cell Therapeutics and Imaging (Cambridge, MA) developed a promising stem cell-based gene therapy to seek, find and destroy glioblastoma tumors.

Read More
E. Antonio Chiocca, MD, PhD: Adapting to the Changing Landscape of Cancer

Years Funded: 2008-2012

Development of an Oncolytic Virus with Prodrug-Activating Gene Therapy
To advance a novel strategy for engineering a virus to work in combination with a patient’s own immune system and the chemotherapy drug cyclophosphamide (CPA), E. Antonio Chiocca, MD, PhD, completed important preclinical toxicity studies at The Ohio State University Research Foundation (Columbus, OH). His research determined the safety of this approach for fighting glioblastoma and generated the data necessary to apply to the U.S. Food and Drug Administration for permission to launch a phase one clinical trial.

Read More
Maciej S. Lesniak, MD: Necessity is the Mother of Invention

Years Funded: 2007-2010

Development of a Novel Oncolytic Virus for Malignant Glioma
More than a decade ago, ACGT helped launch Maciej S. Lesniak, MD, onto an innovative research trajectory aimed at harnessing re-engineered cold virus to selectively infect and ultimately destroy cancer cells in the brain without harming other healthy cells.

Read More
Miguel Sena Esteves, PhD: Taking an Engineering Approach to Biology

Years Funded: 2006-2009

Engineering the Brain Microenvironment for Brain Tumor Therapy
With a team at Massachusetts General Hospital (Charlestown, MA), Miguel Sena-Esteves, PhD, began a successful career exploring how to use a viral strategy to create a zone of resistance in the brain where normal tissue could be modified to prevent tumors from growing, and ultimately, to destroy them. His ACGT-funded studies demonstrated that adeno-associated viral (AAV) vectors could do the job, but not without long-term toxicity consequences.

Read More

Join the Alliance

  • This field is for validation purposes and should be left unchanged.